Tonapofylline (Synonyms: BG 9928) |
رقم الكتالوجGC37815 |
Tonapofylline (BG 9928) هو مضاد لمستقبلات الأدينوزين A1 النشط عن طريق الفم والانتقائي مع Ki 7.4 نانومتر لمستقبل الأدينوزين البشري A1 (hA1) ، والذي يعرض انتقائية 915 ضعفًا مقابل مستقبل الأدينوزين البشري A2A والانتقائية 12 ضعفًا مقابل الأدينوزين البشري A2B مستقبل ويستخدم في التنمية لعلاج قصور القلب
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 340021-17-2
Sample solution is provided at 25 µL, 10mM.
Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2]. Ki: 7.4 nM (Human adenosine A1 receptor)[1]
Tonapofylline (BG 9928) (1 mg/kg; p.o., b.i.d, days 0-6) produces sustained reductions in post-Cisplatin serum creatinine and blood urea nitrogen levels, improves body weight recovery and significant attenuation of Cisplatin-induced (5.5 mg/kg) kidney pathology scores[3]. Animal Model: Female viral antigen-free Sprague-Dawley rats[3]
[1]. Kiesman WF, et al. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. [2]. Ensor CR, et al. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010 Oct;11(14):2405-15. [3]. Gill A, et al. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol. 2009;30(6):521-6.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *